Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

67%

6 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 3

5(62.5%)

Phase 1

2(25.0%)

Phase 4

1(12.5%)

8Total

Phase 3(5)

Phase 1(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07092813Phase 1Recruiting

Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents

Role: lead

NCT05584657Phase 3Completed

Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women

Role: lead

NCT04682834Unknown

Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection

Role: lead

NCT04700787Phase 1Withdrawn

Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents

Role: lead

NCT05026801Phase 3Withdrawn

Azithromycin Plus Hydroxychloroquine for COVID-19 Infection

Role: lead

NCT03354598Phase 3Completed

Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women

Role: lead

NCT03357614Phase 3Completed

Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

Role: lead

NCT03358576Phase 3Completed

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

Role: lead

NCT03366207Phase 4Completed

Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)

Role: lead

All 9 trials loaded